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Calycosin and formononetin are two structurally similar isoflavonoids that have been shown to induce vasodilation in aorta and
conduit arteries, but study of their actions on endothelial functions is lacking. Here, we demonstrated that both isoflavonoids
relaxed rat mesenteric resistance arteries in a concentration-dependent manner, which was reduced by endothelial disruption
and nitric oxide synthase (NOS) inhibition, indicating the involvement of both endothelium and vascular smooth muscle. In
addition, the endothelium-dependent vasodilation, but not the endothelium-independent vasodilation, was blocked by BKCa
inhibitor iberiotoxin (IbTX). Using human umbilical vein endothelial cells (HUVECs) as a model, we showed calycosin and
formononetin induced dose-dependent outwardly rectifying K+ currents using whole cell patch clamp. These currents were
blocked by tetraethylammonium chloride (TEACl), charybdotoxin (ChTX), or IbTX, but not apamin. We further demonstrated
that both isoflavonoids significantly increased nitric oxide (NO) production and upregulated the activities and expressions of
endothelial NOS (eNOS) and neuronal NOS (nNOS). These results suggested that calycosin and formononetin act as endothelial
BKCa activators for mediating endothelium-dependent vasodilation through enhancing endothelium hyperpolarization and NO
production. Since activation of BKCa plays a role in improving behavioral and cognitive disorders, we suggested that these two
isoflavonoids could provide beneficial effects to cognitive disorders through vascular regulation.
1. Introduction
Calycosin and formononetin (Figure 1) are two structurally
similar isoflavonoids that are present abundantly in tradi-
tional Chinese medicine (TCM) such as Radix Astragali
(Huang Qi) and phytoestrogenic herb including Trifolium
pretense L. (red clover), and they have a long clinical history
in treating various cardiovascular diseases [1, 2]. Previous
studies have shown that calycosin and formononetin pro-
duced antihypertensive effects and improved endothelial
and cardiovascular functions [3–6]. They have been shown
to display vasoactive effects in various vascular beds [3,
5–7]. In rat aorta, calycosin induced vasodilation mainly
by inhibiting voltage-dependent Ca2+ channel (VDCC) in
vascular smooth muscle [7], while formononetin caused
vasodilation by releasing nitric oxide (NO) in endothelial
cells, as well as by the activation of large-conductance Ca2+-
activated K+ (BKCa) and ATP-sensitive potassium (KATP)
channels in aortic smooth muscle cells [6]. In addition,
these two isoflavonoids were reported to ameliorate cerebral
ischemia and reperfusion injury by improving endothelial
dysfunction [8, 9].These observation led us to investigate the
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Figure 1: Chemical structures of calycosin and formononetin.
pharmacological underlying mechanisms of calycosin and
formononetin in small resistance arteries (internal diameter
≤ 300 𝜇m) and vascular endothelial cells.
Small resistance arteries are major sites of peripheral vas-
cular resistance and are closely related to endothelial dysfunc-
tion and the pathogenesis of hypertension [10, 11]. Interest-
ingly, it has been shown that endothelium-dependent hyper-
polarization (EDH)wasmore pronounced in small resistance
arteries than large conduit arteries such as aorta [10, 12].
In the vascular walls, calcium-activated potassium (KCa)
channel is the main contributor for endothelium-derived
hyperpolarizing factor- (EDHF-) mediated responses, which
plays a crucial role in the regulation of vascular tone and
themaintenance of systemic blood pressure [13, 14]. Recently,
endothelial KCa channels have been used as new drug
targets for cardiovascular diseases such as hypertension to
stimulate EDHF and NO production to improve endothelial
dysfunction [13, 15–17].There are three types of KCa channels
based on their conductances, including IKCa (intermediate
conductance), SKCa (small conductance), and BKCa (large
conductance) [18]. Although IKCa and SKCa are the major
KCa channels present in the endothelial cells of arteries,
BKCa channels have been identified in the endothelium of
rat pulmonary and mesenteric arteries [19, 20] and cultured
endothelial cells [21, 22]. It has been suggested that BKCa
channel has a compensatory role for improving vasoreactivity
in environment such as hypertension and cardiovascular
diseases [23, 24]. In addition, it was shown that BKCa
channel acts as a negative feedback mechanism for vascular
dysfunction impaired by reactive oxygen species (ROS)
and is overexpressed in diseases associated with endothelial
dysfunction [25–27].
In the present study, we investigated the effects of
calycosin and formononetin in rat mesenteric resistance
arteries and their underlying mechanisms with a focus on
endothelial K+ channel. We demonstrated that calycosin and
formononetin induced endothelium-dependent vasodilation
through NO production and BKCa channel activation. We
also showed that calycosin and formononetin increased
NO production through endothelial nitric oxide synthase
(eNOS) and neuronal nitric oxide synthase (nNOS) pathway
and activated endothelial BKCa channels in human umbil-
ical endothelial cells (HUVEC). Taken together, our study
demonstrated that calycosin and formononetin are endothe-
lial BKCa channel activators, suggesting a novel mechanism
for vasodilation by these isoflavones, and they might be
potential for treating vascular and cerebrovascular diseases
associated with endothelial dysfunction.
2. Material and Methods
2.1. Chemicals and Reagents. Calycosin and formononetin
were purchased from Shanghai Forever Biotech (Shanghai,
China), and they were dissolved in dimethyl sulphoxide
(DMSO). All the chemicals were purchased from Sigma-
Aldrich (St. Louis, MO, USA), while the cell culture reagents
were from Gibco (Carlsbad, CA, USA). All the antibodies
used for immunoblottingwere purchased fromCell Signaling
Technology (Danvers, MA, USA).
2.2. Animals. All the procedures were carried out according
to the ethical guidelines of the Institute of Chinese Medical
Sciences (ICMS), University ofMacau, andNIH guide for the
Care and Use of Laboratory Animals. Male Sprague-Dawley
rats (250 ± 350 g) were killed by cervical dislocation.
2.3. Preparation of Resistance Mesenteric Arteries. The
mesenteric arterial bedswere dissected from rats immediately
after cervical dislocation and were kept in cold Krebs–
Henseleit buffer with the following compositions (mM):
NaCl, 118; KCl, 4.7; MgSO
4
, 1.2; KH
2
PO
4
1.2; NaHCO
3
,
25; CaCl
2
, 2.5; D-glucose, 5.5. The Krebs–Henseleit buffer
was continuously gassed with a mixture of 95% O
2
/5%
CO
2
to maintain a pH of 7.4. Small (the third branches of
the mesenteric artery) mesenteric arteries were placed in
a 4-chamber wire myograph (DMT, Tissue Bath System
700MO, Aarhus, Denmark) and were maintained at 37∘C in
Krebs–Henseleit buffer.The normalized protocol was used as
described previously [28]. The tension was recorded by the
PowerLab recording system (ADInstruments, Hastings, UK).
In endothelium-denuded experiments, the endothelium was
removed by rubbing the inner surface of the segment
with human hair. In endothelium-intact experiments, the
presence of a functional endothelium was examined by
precontracting the arteries with methoxamine (10 𝜇M) and
then was relaxed by carbachol (10𝜇M), and this vasodilation
was greater than 80%.
2.4. Myograph Experimental Protocol. After 30min equili-
bration, arteries were firstly precontracted by methoxamine
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(10 𝜇M). Once the tension was stable, calycosin (1 nM–
100 𝜇M) and formononetin (1 nM–100 𝜇M) were added
cumulatively to produce a concentration-dependent response
in endothelium-intact and endothelium-denudedmesenteric
arteries. The effects of vasodilation in response to calycosin
and formononetin were also examined with preincubation of
indomethacin, N
𝜔
-nitro-l-arginine methyl ester (L-NAME),
tetraethylammonium chloride (TEACl), apamin, charybdo-
toxin (ChTX), iberiotoxin (IbTX), and glibenclamide for
30min, before precontracting with methoxamine. In some
experiments, the arteries were precontracted with high K+
(60mMKCl) Krebs–Henseleit buffer by replacing NaCl with
KCl in the standard Krebs–Henseleit solution, as described
previously [28].
2.5. Cell Culture. Human umbilical vein endothelial cells
(HUVECs) were purchased from Life Technologies (Carls-
bad, CA, USA) and were cultured in Hams F-12k nutrient
medium supplemented with 15% fetal bovine serum, 1%
penicillin-streptomycin, 100mg/mL heparin, and 10mg/mL
endothelial cell growth supplement (Sigma-Aldrich, St. Louis,
MO, USA) at 37∘C under an atmosphere of 5% CO
2
in air.
The cells were used in passages 2–6. Plated cells were allowed
to adhere for 2 h before patch clamp experiments. For the
experiments measuring NO production, and the expressions
of different nitric oxide synthases (NOS), calycosin and
formononetin were treated for 1 h in HUVEC.
2.6. NO Production Assay. NO was measured by a Nitric
Oxide Assay Kit (Abcam, Cambridge, UK) following the
manufacturer’s instruction. Briefly, 75 𝜇L of cell supernatants
was mixed with 5𝜇L enzyme cofactor solution and 5 𝜇L
nitrate reductase. Following 2 h of incubation for converting
nitrates to nitrites, 5𝜇L enhancer was added to each sample
and incubated for 30min. 5 𝜇L DAN Probe was then added
and incubated for 10min. After that, 5 𝜇L NaOH was added
in the mixture for 10min. The fluorescence intensity was
detected by a microplate reader (SpectaMax M5, Molecular
Devices, USA) using excitation at 360 nm and emission at
450 nm wavelengths.
2.7. Patch Clamp Experiments. All the cells were superfused
with the extracellular solution with the following com-
positions (mM): NaCl, 140; KCl, 5.4; CaCl
2
, 1.8; MgCl
2
,
1; NaH
2
PO
4
0.33; HEPES, 5; D-glucose, 5.5; pH 7.4. The
recordings were made by using an Axopatch-200B amplifier,
Digidata-1321 interface, and pClamp10.0 software (Axon
Instruments, Forster City, CA). In the outward K+ channel
experiment, the pipettes (resistance 2-3MΩ) were filled with
intracellular pipette solution (mM): KCl, 140; MgCl
2
, 2.5; D-
glucose, 10; HEPES, 5; pH 7.2. In some experiments, [Ca2+]i
was adjusted to 250, 500, or 1000 nM by administrating 6.7,
8.0, or 8.9mM CaCl
2
to the intracellular pipette solution,
respectively, and in the presence of 10mM EGTA. The
cells were clamped at a holding potential of −60mV and
various potential steps from −100mV to +100mVwith 10mV
increments, and the currents were stimulated by a series of
250ms.
2.8. [Ca2+]i Measurements. The intracellular Ca2+ concen-
tration ([Ca2+]i) was measured in single cells as previ-
ously described [29]. Cells were loaded with Fluo-4 AM
(2 𝜇M, Molecular Probes, US) in Tyrode solution containing
136.5mMNaCl, 5.4mMKCl, 0.53mMMgCl
2
, 1.8mMCaCl
2
,
0.33mM NaH
2
PO
4
, 5.5mM glucose, and 5.5mM HEPES
(pH 7.4, adjusted with NaOH) for 30min at 37∘C. Fluo-4
fluorescence intensity (494 nm excitation; 506 nm emission)
was sampled at 5 s intervals using a CellR system (MT20,
Olympus, US).
2.9. Western Blot Analysis. After indicated treatment, the
protein was extracted with ice-cold lysis buffer, and the
concentrations of lysates were measured by the bicinchoninic
acid kit (Pierce, US). 30 𝜇g proteins were used and sep-
arated by 10% SDS-PAGE gels and were transferred onto
the nitrocellulose membranes. Membranes were incubated
with primary antibodies (eNOS, p-eNOS, nNOS, and iNOS
antibody using 1/1000 dilution, whereas GAPDH antibody
using 1/4000 dilution) overnight at 4∘C, and secondary
antibodies (anti-rabbit with 1/1000 dilution) for 1 hr, and
blots were developed by enhanced chemiluminescence (GE
Healthcare Life Sciences, UK) with an imaging system (Bio-
Rad Laboratories, USA). GAPDHwere used as housekeeping
controls.
2.10. Data and Statistical Analysis. Data were expressed as
mean ± SEM. vasodilation responses in each segment were
expressed as a percentage of relaxation. The dose-response
curves were fitted to a logistic equation described previously
[30]. The maximum percentage of relaxation (𝑅max) and the
concentration required to produce 50% of maximal response
tone (EC
50
) were calculated from the fitted curves. Currents
curves were fitted by Boltzmann equations. The curve fitting
and statistical analyzes were determined using GraphPad
Prism 5 (San Diego, CA, USA). Significant differences were
analyzed by 𝑡-test, one-way ANOVA followed by a Dunnett’s
test, or two-way ANOVA followed by a Bonferroni post hoc
test. 𝑃 < 0.05 was considered as significant.
3. Results
3.1. Effects of Endothelial Removal, L-NAME, and K+ Channel
Inhibitors onVasodilation inResponse toCalycosin. Calycosin
induced dose-dependent vasodilation with methoxamine
(10 𝜇M) precontraction in endothelium-intact small mesen-
teric arteries (Figure 2(a), EC
50
= 7.7 ± 0.05 𝜇M, 𝑅max =
87.9±2.0%; 𝑛 = 6).The removal of endothelium significantly
reduced this effect (Figure 2(a), EC
50
= 28.6 ± 0.12 𝜇M,
𝑅max = 51.3 ± 4.5%; 𝑛 = 6). Next, we examined whether
endothelium-derived NO was involved in this vasodilation.
Preincubation with L-NAME (300 𝜇M), a nitric oxide syn-
thase inhibitor, partially reduced calycosin-induced vasodila-
tion (Figure 2(b), EC
50
= 40.4±0.08 𝜇M, 𝑅max = 75.6±3.4%;
𝑛 = 5). Notably, as shown in Figure 2(b), the inhibitory effects
of endothelium denudation and L-NAME preincubation
on calycosin-induced vasodilation were similar. However,
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Figure 2: Concentration-response curves for calycosin-induced relaxation in the rat mesenteric arteries. (a) Vasorelaxation induced by
calycosin with DMSO vehicle, or in the presence and absence of endothelium (∗∗𝑃 < 0.01; ##𝑃 < 0.01). (b) Calycosin-induced vasorelaxation
in the presence and absence of endothelium, or L-NAME (300𝜇M) pretreatment in endothelium-intact arteries (∗𝑃 < 0.05; #𝑃 < 0.05 versus
endothelium denuded). (c, d) Calycosin-induced vasorelaxation with pretreatments of either TEACl (3mM; ∗∗𝑃 < 0.01), glibenclamide
(10𝜇M), apamin (50 nM) plus ChTX (50 nM), or IbTX (200 nM; ∗∗𝑃 < 0.01). (e) Calycosin-induced vasorelaxation with IbTX (200 nM)
pretreatment in endothelium-denuded arteries. (f) Calycosin-induced vasorelaxation with precontractions by methoxamine (10𝜇M) or KCl
(60mM; ∗∗𝑃 < 0.01) in endothelium-intact arteries. Data were shown as mean ± SEM. ChTX, charybdotoxin; IbTX, iberiotoxin; TEACl,
tetraethylammonium chloride.
indomethacin (10𝜇M), cyclooxygenase inhibitor, did not
affect the vasodilation by calycosin (data not shown).
Next, we examined whether K+ channels were also
involved in calycosin-induced vasodilation. With pretreat-
ment of TEACl (3mM), a nonspecific inhibitor of K+ chan-
nels, the vasodilation effect was significantly reduced when
compared to control (Figure 2(c), EC
50
= 25.1 ± 0.12 𝜇M,
𝑅max = 58.3 ± 5.1%; 𝑛 = 6). Similarly, pretreatment with
BKCa channel inhibitor, IbTX (200 nM), significantly reduced
calycosin-induced vasodilation (Figure 2(d), EC
50
= 28.3 ±
0.08 𝜇M, 𝑅max = 44.5 ± 3.9%; 𝑛 = 6). However, with
pretreatment of KCa channel inhibitors, apamin (50 nM) plus
ChTX (50 nM), the vasodilation was reduced to a smaller
extent (Figure 2(d), EC
50
= 20.7 ± 0.12 𝜇M, 𝑅max =
56.0 ± 4.3%; 𝑛 = 6). Conversely, glibenclamide (10𝜇M), a
KATP channel inhibitor, had no effect on calycosin-induced
vasodilation (Figure 2(c), EC
50
= 8.9±0.08 𝜇M,𝑅max = 76.4±
6.2%; 𝑛 = 6). Surprisingly, pretreatment with IbTX (200 nM)
in endothelium-denuded arteries had no effect on calycosin-
induced vasodilation (Figure 2(e)). Furthermore, calycosin-
induced vasodilation was reduced with KCl (60mM) pre-
contraction compared to methoxamine precontraction in
endothelium-intact arteries (Figure 2(f), EC
50
= 8.06 ±
0.08 𝜇M, 𝑅max = 58.5 ± 4.8%; 𝑛 = 5). These data showed
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Figure 3: Concentration–response curves for formononetin-induced relaxation in the rat mesenteric arteries. (a) Formononetin-induced
vasorelaxation with DMSO vehicle, or in the presence and absence of endothelium (∗∗𝑃 < 0.01; ##𝑃 < 0.01). (b) Formononetin-induced
vasorelaxation in the presence and absence of endothelium, or L-NAME (300𝜇M) preincubation in endothelium-intact arteries (∗∗𝑃 < 0.01;
#
𝑃 < 0.05 versus endothelium denuded). (c, d) Formononetin-induced vasorelaxation with pretreatments of either TEACl (3mM; ∗∗𝑃 <
0.01), glibenclamide (10 𝜇M; ##𝑃 < 0.01), apamin (50 nM) plus ChTX (50 nM; ∗∗𝑃 < 0.01), or IbTX (200 nM; ##𝑃 < 0.01). (e) Formononetin-
induced vasorelaxation with IbTX (200 nM) preincubation in endothelium-denuded arteries. (f) Formononetin-induced vasorelaxation with
precontractions of methoxamine (10𝜇M) or KCl in endothelium-intact arteries (60mM; ∗∗𝑃 < 0.01). Data were shown as mean ± SEM.
ChTX, charybdotoxin; IbTX, iberiotoxin; TEACl, tetraethylammonium chloride.
that calycosin induced vasorelaxation via both endothelium-
dependent and endothelium-independent pathways. More
interestingly, the data also suggested that BKCa channels are
closely related to the endothelium-dependent vasorelaxation.
3.2. Effects of Endothelial Removal, L-NAME, and K+ Channel
Inhibitors on Vasodilation in Response to Formononetin. For-
mononetin also induced concentration-dependent vasodila-
tion after methoxamine (10 𝜇M) precontraction (Figure 3(a),
EC
50
= 9.6±0.12 𝜇M,𝑅max = 79.9±3.4%, 𝑛 = 6), and removal
of the endothelium (Figure 3(a), EC
50
= 13.9 ± 0.09 𝜇M,
𝑅max = 63.6 ± 3.2%, 𝑛 = 6) or preincubation with L-NAME
(300 𝜇M) (Figure 3(b), EC
50
= 42.8 ± 0.30 𝜇M, 𝑅max = 56.3 ±
4.5%, 𝑛 = 5) significantly reduced this effect. On the other
hand, indomethacin (10 𝜇M) did not affect this vasodilation
(data not shown).
As shown in Figure 3(c), formononetin-induced vasodi-
lation was significantly inhibited with pretreatments of
TEACl (3mM, EC
50
= 24.3 ± 0.20 𝜇M, 𝑅max = 50.8 ± 4.6%;
𝑛 = 6) or glibenclamide (10 𝜇M, EC
50
= 6.67 ± 0.12 𝜇M,
𝑅max = 45.4 ± 3.9%; 𝑛 = 7). The vasodilation effect by form-
ononetin was also reduced with pretreatment of IbTX
(200 nM), or the combination of apamin plus ChTX (both
50 nM, Figure 3(d), IbTX: EC
50
= 23.7 ± 0.18 𝜇M,
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𝑅max = 43.6 ± 4.2%; 𝑛 = 6; 𝑃 < 0.01; A+C: EC50 =
27.8 ± 0.17 𝜇M, 𝑅max = 48.9 ± 4.0%; 𝑛 = 6). In addi-
tion, pretreatment with IbTX (200 nM) did not affect
formononetin-induced vasodilation in endothelium-den-
uded arteries (Figure 3(e)). Formononetin-induced vasodi-
lation was significantly reduced with KCl (60mM) pre-
contraction compared to methoxamine precontraction in
endothelium-intact arteries (Figure 3(f), EC
50
= 4.38 ±
0.05 𝜇M, 𝑅max = 53.5 ± 3.9%, 𝑛 = 5). Similar to the
effects of calycosin, these data showed that formononetin
induced vasorelaxation via both endothelium-dependent and
endothelium-independent pathways. More interestingly, the
data also suggested that BKCa channels are closely related to
the endothelium-dependent vasorelaxation.
3.3. Effect of Calycosin and Formononetin on NO Production
and eNOS, iNOS, and nNOS Expression in HUVEC. In order
to further determine whether these two isoflavonoids could
regulate the production of NO and the expression of NOS
in endothelial cells, HUVEC was employed as a cellular
model. HUVEC is a widely in vitro cell model for the study
of the regulation of endothelial function and the vascular
diseases [31]. Figure 4(a) showed that calycosin increased
NO production in a dose-dependent manner in HUVEC,
and similar effect was also observed with formononetin
(Figure 4(b)). There are three isoforms of NOS, including
eNOS, inducible nitric oxide synthase (iNOS), and nNOS,
which are responsible for the generation of NO in the
vascular endothelium [32]. It has been reported that eNOS
and nNOS are coexpressed in endothelial cells while iNOS
is not [33]. Our results demonstrated that both calycosin
(100 𝜇M) and formononetin (100 𝜇M) significantly induced
the activation of eNOS (Figures 4(c) and 4(d)). In addi-
tion, both isoflavonoids also upregulated nNOS expression
(Figures 4(c) and 4(d)). In contrast, iNOS expression was
unaffected by neither calycosin nor formononetin (Figures
4(c) and 4(d)). These data suggested that calycosin and for-
mononetin induced endothelium-dependent vasorelaxation
via NO production through eNOS and nNOS.
3.4. Effect of Calycosin on Outward Currents in HUVEC.
The activation of KCa is the major mechanism for EDH. We
observed that exposure of calycosin induced dose-dependent
outward currents in HUVEC recorded by whole cell patch
clamp.Thewhole cell currents ofHUVECwere recordedwith
250ms voltage steps between −100mV and +100mV from a
holding potential of −60mV. As shown in Figures 5(a) and
5(b), calycosin (10 nM–100𝜇M) increased dose-dependent
outward currents in HUVEC (𝑛 = 9). At 100 𝜇M calycosin,
the current at +100mV was significantly increased (Figures
5(a) and 5(c), 31.2 ± 1.7 pA/pF; 𝑛 = 7) compared to control
(9.9±1.0 pA/pF), and this current was abolished by TEACl, a
nonspecific inhibitor of K+ channels (1mM, Figures 5(c) and
5(e); 11.6 ± 1.5 pA/pF; 𝑛 = 6).
Although IKCa and SKCa are the major KCa channels
present in the endothelial cells, BKCa is also expressed
moderately, and it was identified in HUVEC [22, 23]. We
observed that KCa channels in calycosin induced outward
currents in HUVEC. An IKCa channel inhibitor, apamin
(100 nM), had no effect on the outward currents induced by
calycosin (Figure 5(e), 𝑛 = 6). However, it was abolished
by BKCa inhibitors, IbTX (200 nM, Figures 5(d) and 5(e);
13.8 ± 2.8 pA/pF; 𝑛 = 6) and ChTX (200 nM, Figure 5(e);
14.9 ± 0.9 pA/pF; 𝑛 = 7). In addition, by maintaining [Ca2+]i
at 250 nM, 500 nM, or 1000 nM, calycosin (100 𝜇M) signif-
icantly increased the outward currents stimulated by single
+100mV step, compared with Ca2+-free solution containing
10mM EGTA (Figure 5(f), 𝑛 = 7–9). These data strongly
suggested that calycosin mainly activated endothelial BKCa
channels but has minimal effects on IKCa or SKCa.
3.5. Effect of Formononetin on Outward Currents in HUVEC.
It was observed that formononetin (10 nM–100 𝜇M) signif-
icantly increased the outward currents in a concentration-
dependent manner in HUVEC, similar to the effects of
calycosin (Figures 6(a) and 6(b), 𝑛 = 6-7). At 100 𝜇M,
formononetin significantly increased the outward currents
compared to control at +100mV step (Figure 6(a), control:
1.4 ± 1.6 pA/pF, formononetin: 36.4 ± 3.1 pA/pF; 𝑛 = 6).
This current was abolished by TEACl (1mM, Figures 6(c),
and 6(e); 15.7 ± 3.6 pA/pF; 𝑛 = 6), or IbTX (200 nM, Figures
6(d) and 6(e), 14.1 ± 0.9 pA/pF; 𝑛 = 5), or ChTX (200 nM,
Figure 6(e), 14.1 ± 0.9 pA/pF; 𝑛 = 5). However, apamin
(100 nM, Figure 6(e), 37.1 ± 3.2 pA/pF; 𝑛 = 6) had no effect
on these outward currents. Maintaining [Ca2+]i at 250 nM,
500 nM, or 1000 nM, formononetin (100 𝜇M) significantly
increased the outward currents at +100mV compared with
Ca2+-free solution containing 10mM EGTA (Figure 6(f), 𝑛 =
6). These data suggested that formononetin mainly activated
endothelial BKCa channels but has minimal effects on IKCa or
SKCa.
3.6. Effect of Calycosin and Formononetin on [Ca2+]i in
HUVEC. Endothelial [Ca2+]i elevation has been implicated
in endothelium-mediated vasodilation [18] and is also needed
for KCa activation [34]. Since calycosin and formononetin
increased outward currents via endothelial KCa channel,
we next examined their effects on [Ca2+]i in HUVEC. As
expected, we observed a rapid increase in [Ca2+]i in response
to calycosin (Figures 7(a) and 7(b)). Similar results also
showed that formononetin evoked Ca2+ influx (Figures 7(a)
and 7(b)). Both of these two drugs induced approximately
45% increases in [Ca2+]i compared to untreated cells. There-
fore, these data suggested that calycosin and formononetin
activated endothelial BKCa channels probably by increasing
[Ca2+]i.
4. Discussion
In the present study, we investigated the endothelial beneficial
effects of calycosin and formononetin, two isoflavonoids
isolated from the well-known antihypertensive herb, Radix
Astragali, in rat small resistance arteries and HUVEC. The
chemical structures of calycosin and formononetin are very
similar, with an extra hydroxyl group at C-3 position of
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Figure 4: Calycosin and formononetin inducedNOproduction via eNOS and nNOS pathways inHUVEC. (a, b) NO level was determined by
a NO assay kit. HUVEC was incubated with DMSO, calycosin (1–100 𝜇M), or formononetin (1–100 𝜇M) for 1 h (𝑛 = 5). (c, d) Representative
immunoblots and graphs for the protein expressions of eNOS, phosphorylation of eNOS, nNOS, iNOS, or GAPDH after (c) calycosin (1–
100 𝜇M) or (d) formononetin (1–100 𝜇M) treatment for 1 h (𝑛 = 3-4). Data were shown as mean ± SEM. ∗𝑃 < 0.05, ∗∗∗𝑃 < 0.001 versus
untreated cells.
the B-ring in calycosin [35]. Both isoflavonoids were shown
to provide beneficial effects in vascular tone regulation and
improvement in endothelial and cardiovascular dysfunction
[3–6].
Here, we demonstrated that calycosin and formononetin
produced very similar effects in rat small mesenteric arter-
ies, that is, inducing vasorelaxation through endothelium-
dependent and endothelium-independent pathways. We
observed that relaxations elicited by both isoflavonoids could
be reduced by endothelial disruption and were sensitive
to L-NAME (inhibitor of NOS), apamin plus charybdo-
toxin (inhibitors of SKCa and IKCa), and iberiotoxin (IbTX)
(inhibitor of BKCa). Notably, the sensitivity to IbTX was only
observed in endothelium-intact, but not in endothelium-
denuded vessels, indicating the involvement of BKCa channels
present in the endothelium. The relaxation elicited by both
isoflavonoids was also reduced (to a lesser extent) when the
arteries were contracted with high KCl (60mM) depolar-
izing solution, indicating the inhibition of VDCC was also
partly involved. Pretreatment with indomethacin to inhibit
prostaglandin production did not affect the vasodilation,
indicating that PGI
2
was not involved. Although calycosin
and formononetin are very similar in structure, differential
properties of their effects were also observed. Our data
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Figure 5: Calycosin increased outward currents in HUVEC through BKCa channel. (a) Current-voltage (𝐼/𝑉) relationship in response to
calycosin (1–100 𝜇M). (b) Dose-response curve for whole cell recording of currents at +100mV with different concentrations of calycosin
(10 nM–100𝜇M). (c, d) Representative trace of currents that were recorded in response to calycosin in the absence or presence of (c) TEACl
(1mM) or (d) IbTX (200 nM). (e, f) Whole cell recording of currents at +100mV in response to calycosin (100𝜇M) in the presence of (e)
apamin (200 nM), IbTX (200 nM), ChTX (200 nM), or TEACl (1mM; ∗∗∗𝑃 < 0.001 versus control; ##𝑃 < 0.01 and ###𝑃 < 0.001 versus
calycosin-treated cells), or (f) with different [Ca2+]i as indicated (
∗∗
𝑃 < 0.01 and ∗∗∗𝑃 < 0.001 versus calycosin-treated cells with free
[Ca2+]i). Data were shown as mean ± SEM. ChTX, charybdotoxin; IbTX, iberiotoxin; TEACl, tetraethylammonium chloride.
showed that relaxation induced by formononetin was sen-
sitive to glibenclamide (KATP channel inhibitor), but not
calycosin-induced relaxation. Besides, we also observed some
discrepancies in the effects of calycosin and formononetin
in blood vessels from various vascular beds. Previous study
intact aortic rings reported that the relaxation elicited by
calycosin was endothelium-independent by acting as Ca2+
channel blocker [7]. However, here in rat mesenteric arter-
ies we observed that calycosin-elicited relaxation is both
endothelium-dependent and endothelium-independent. For
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Figure 6: Formononetin increased outward currents in HUVEC through BKCa channel. (a) 𝐼/𝑉 graph in response to formononetin (1–
100 𝜇M). (b) Dose-response curve for whole cell recording of currents at +100mV with different concentrations of formononetin (10 nM–
100 𝜇M). (c, d) Representative trace of currents that were recorded in response to formononetin, in the absence and presence of (c) TEACl
(1mM) or (d) IbTX (200 nM). (e, f) Whole cell recording of currents at +100mV in response to formononetin (100𝜇M) in the presence of
(e) apamin (200 nM), IbTX (200 nM), ChTX (200 nM), or TEACl (1mM; ∗∗∗𝑃 < 0.001 versus control; ##𝑃 < 0.01 and ###𝑃 < 0.001 versus
formononetin-treated cells), or (f) with different [Ca2+]i as indicated (
∗∗∗
𝑃 < 0.001 versus formononetin-treated cells with free [Ca2+]i). Data
were shown as mean ± SEM. ChTX, charybdotoxin; IbTX, iberiotoxin; TEACl, tetraethylammonium chloride.
formononetin, results from previous studies in rat aor-
tic rings showed that formononetin elicited relaxation
through endothelium-dependent pathway involvingNO syn-
thesis, and endothelium-independent involving iberiotoxin-
(IbTX-) sensitive BKCa channel, glibenclamide-sensitive
KATP channel, and the inhibition of VDCC [5, 6, 36]. Here
in rat mesenteric arteries, we observed very similar effects of
formononetin, but in our preparation the sensitivity to IbTX
was only observed in endothelium-intact vessels, indicating
a more important role of endothelial BKCa channels in the
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Figure 7: Calycosin and formononetin-induced Ca2+ response
in HUVEC. (a, b) HUVEC was loaded with Fluo-4 in Tyrode
solution containing 2mM Ca2+. Representative graph and relative
fluorescence intensity in intracellular Ca2+ concentration ([Ca2+]i),
evoked by calycosin (100𝜇M) and formononetin (100 𝜇M) over the
time course (𝑛 = 3). Data were shown as mean ± SEM. ∗𝑃 < 0.05
versus control.
mesenteric resistance arteries. The discrepancies observed
for calycosin and formononetin in rat aorta and mesenteric
arteries may be explained by the differential physiological
characteristics exhibited by conduit and resistance arteries
for vascular homeostasis. In fact, it has been recognized that
endothelium-dependent vasoactivities are more pronounced
in small resistance arteries than in large conduit arteries such
as aorta, and small resistance arteries are closely related to
endothelial dysfunction [10, 12]. Thus, our results suggested
that calycosin and formononetin could effectively promote
endothelial functions in the small resistance arteries, and
endothelial BKCa channels might have an important role.
BKCa channels are mainly expressed in vascular smooth
muscle cells, but recent studies demonstrated that BKCa
channels are also present in vascular endothelium or freshly
isolated endothelial cells from the small resistance arteries
[19, 20]. When expressed in endothelial cells, BKCa channels
are observed to regulate NO and EDH production, and their
important roles have been implicated in disease conditions
such as ischemic hypoxia [19, 23, 37, 38]. In line with
this, we demonstrated that both calycosin and formononetin
significantly increased NO production and upregulated the
activities and expressions of eNOS and nNOS, without affect-
ing iNOS in HUVEC. It has been suggested that endothelial
BKCa channel might serve as a compensatory mechanism
for improving vasoreactivity in disease environments such as
hypertension and could be a potential therapeutic target for
the regulation of blood pressure and flow through increased
NO production vascular hyperpolarization [20, 39].
By using whole cell patch clamp, we further showed that
IbTX-sensitive outward-rectifying currents were induced by
exposure to calycosin or formononetin in a dose-dependent
manner in HUVEC, an endothelial cell model commonly
used for endothelial functions.Moreover, these currents were
also sensitive to charybdotoxin (also an inhibitor at BKCa
channel), but not apamin (selective SKCa channel inhibitor).
Buffering intracellular Ca2+ by EGTA significantly reduced
calycosin- and formononetin-induced outward currents,
indicating that the activation of the K+ channels was depen-
dent on intracellular calcium which further indicated the
characteristic of BKCa channel [40].We further demonstrated
that calycosin and formononetin could induced an [Ca2+]i
increase inHUVEC, providingmore evidences that calycosin
and formononetin activate endothelial BKCa channel by
stimulating [Ca2+]i increase.
Until recently, the emerging view of cerebrovascular
dysregulation was implicated not only in cerebrovascular
diseases, such as stroke, but also in neurodegeneration, like
Alzheimer’s disease (AD) [41]. Particularly, the inhibition of
BKCa activity was observed in 3xTg AD model mice and
might be involved in early dysfunction in the AD brain [42].
Several studies suggested that the activation of BKCa channels
might be new therapeutic target for improving behavioral and
cognitive disorders [43, 44]. Since our results demonstrated
that calycosin and formononetin act as novel BKCa activators
and also played a role in the regulation in small resistance
arteries, we postulated these two isoflavonoids might have
potential effects on cognitive disorders through the regula-
tion of cerebralmicrocirculation by activating BKCa channels.
5. Conclusions
In summary, our findings demonstrated that calycosin and
formononetin induced vasodilation in rat small mesenteric
arteries involving both the endothelium and the vascular
smooth muscle. The endothelium-dependent responses were
associated with eNOS/nNOS-dependent NO production and
endothelium hyperpolarization, possibly by directly acti-
vating endothelial BKCa channels. Therefore, we suggested
that these isoflavonoids might provide potential therapeu-
tic regiments to improve endothelial functions for treating
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diseases related to abnormal vascular alteration, such as
hypertension, cardiovascular diseases, and cerebrovascular-
circulation related cognitive disorders such as stroke and
vascular dementia.
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